Pegaptanib sodium for the treatment of ocular vascular disease

Authors: Cunningham Jr, Emmett T; Adamis, Anthony P; Goldbaum, Mauro

Source: Expert Review of Ophthalmology, Volume 2, Number 1, February 2007 , pp. 45-60(16)

Buy & download fulltext article:

Price: $73.00 plus tax (Refund Policy)

Abstract:

Pegaptanib sodium is a selective RNA aptamer that inhibits the 165 isoform of vascular endothelial growth factor (VEGF), a key regulator of pathological vascular growth and permeability and a contributor to vision loss in diseases such as age-related macular degeneration (AMD), diabetic retinopathy and retinal vein occlusion. The development of pegaptanib represented an important achievement in that it was both the first approved anti-VEGF agent for the treatment of ocular disease and the first clinically validated aptamer therapeutic. The safety and efficacy of pegaptanib for the treatment of neovascular AMD were established in the VEGF Inhibition Study in Ocular Neovascularization (VISION) trials. Investigations into the use of pegaptanib have now been expanded to include diabetic macular edema, macular edema secondary to central retinal vein occlusion and other ocular vascular diseases. Pegaptanib is also being used investigationally in combination with other agents.

Keywords: age-related macular degeneration; aptamer; central retinal vein occlusion; diabetic macular edema; diabetic retinopathy; retinal vein occlusion; retinopathy of prematurity; vascular endothelial growth factor

Document Type: Research article

DOI: http://dx.doi.org/10.1586/17469899.2.1.45

Publication date: 2007-02-01

More about this publication?

Expert Review of Ophthalmology provides an important platform for commentary and debate on current and emerging approaches in ocular medicine.
Editorial Board
Information for Authors
Submit a Paper
Subscribe to this Title
Information for Advertisers
Terms & Conditions
Information for Librarians
Free Trials
ingentaconnect is not responsible for the content or availability of external websites